BAM
NVAX icon

Belpointe Asset Management’s Novavax NVAX Stock Holding History

Belpointe Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,260
Closed -$22.6K – 2397
2023
Q1 		$22.6K Buy
3,260
+2,400
+279% +$22.1K ﹤0.01% 2244
2022
Q4 		$8.84K Buy
+860
New +$15.2K ﹤0.01% 2689

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Belpointe Asset Management's NVAX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Novavax (NVAX) in Q2 2023, closing a stake of 3,260 shares — an estimated $22.6K sold.

Belpointe Asset Management first reported a position in NVAX in Q4 2022 and held it in 2 quarters. The position peaked at $22.6K in Q1 2023. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 3,260 Novavax shares in Q2 2023, an estimated $22.6K.
  • Belpointe Asset Management first reported a position in Novavax in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Novavax position peaked at $22.6K in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.